Conference Coverage
Conference Coverage
Anti-TNFs help psoriatic arthritis patients get back to work
Key clinical point: Work disability is a reversible outcome in psoriatic arthritis and improves significantly more with use of anti-TNF drugs than...
Conference Coverage
BSR: Multiple benefits seen with intensive psoriatic arthritis therapy
Conference Coverage
Apremilast meets psoriasis endpoints at week 32
Key clinical point: Oral apremilast beat placebo and showed durable efficacy in patients with moderate to severe plaque psoriasis. Major finding:...
Conference Coverage
Ixekizumab met psoriasis endpoints by week 12, with durable response at 60 weeks
Key clinical point: The investigational anti-IL-17A antibody ixekizumab met its endpoints at week 12 in patients with plaque psoriasis, and showed...
Conference Coverage
Secukinumab beat ustekinumab for psoriasis, with difference by week four
Key clinical point:Secukinumab achieved significantly better responses than ustekinumab in the treatment of moderate to severe psoriasis. Major...
Conference Coverage
Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeks
Key clinical point: At 52 weeks, brodalumab met its PASI 100 endpoint compared with ustekinumab in the pivotal phase III AMAGINE-2 trial. Major...
Conference Coverage
New psoriasis drugs offer treatment advantages
Conference Coverage
Data suggest link between tonsillectomy, psoriasis improvement
Conference Coverage
Survey: Psoriasis/psoriatic arthritis undertreated
Key clinical point: Psoriasis and psoriatic arthritis treatment algorithms are underused, and patients are often undertreated. Major finding:...
Conference Coverage
Ixekizumab linked to decrease in psoriasis-related sexual difficulties
Key clinical point: Psoriasis patients have a high rate of sexual problems they attribute to their skin disease, and which decrease with effective...